Keyphrases
Pancreatic Cancer
100%
Second-line Treatment
100%
Phase II Study
100%
Capecitabine
100%
Lapatinib
100%
Metastatic Pancreatic Cancer
100%
Stable Disease
66%
Epidermal Growth Factor Receptor
50%
Median Progression-free Survival
50%
Human Epidermal Growth Factor Receptor 2 (HER2)
50%
Median Overall Survival
50%
Gemcitabine-refractory
50%
Disease Groups
33%
Resectable Pancreatic Cancer
33%
Therapeutic Target
16%
Disease Progression
16%
Adverse Events
16%
Number of Patients
16%
Overexpression
16%
Diarrhea
16%
ErbB
16%
Overall Survival
16%
Clinical Benefit
16%
Targeted Therapy
16%
FDA-approved Drugs
16%
National Cancer Institute
16%
Gemcitabine
16%
2-cycles
16%
Patient Selection
16%
Predictive Biomarker
16%
Performance Status
16%
Clinical Toxicity
16%
Nausea-vomiting
16%
4-cycle
16%
Safety Profile
16%
Treatment Response
16%
Treatment Toxicity
16%
Objective Response Rate
16%
Receptor Activity
16%
Renal Function
16%
Progression-free Survival
16%
Twice Daily
16%
Combination Therapy
16%
Poor Survival
16%
Growth Factor Receptor Tyrosine Kinase
16%
Hepatic Function
16%
Radiological Response
16%
Tyrosine Kinase Inhibitor
16%
Erlotinib
16%
Difference in Medians
16%
Survival Median
16%
Targets of Interest
16%
RECIST Criteria
16%
Common Toxicity Criteria for Adverse Events
16%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Capecitabine
100%
Lapatinib
100%
Disease
55%
Gemcitabine
44%
Overall Survival
44%
Progression Free Survival
44%
Epidermal Growth Factor Receptor 2
33%
Gamma Urogastrone
33%
Adverse Event
22%
Epidermal Growth Factor Receptor
22%
Malignant Neoplasm
11%
Disease Exacerbation
11%
Biological Marker
11%
Diarrhea
11%
Nausea
11%
Protein Tyrosine Kinase
11%
Combination Therapy
11%
Protein Tyrosine Kinase Inhibitor
11%
Erlotinib
11%
Growth Factor Receptor
11%